Precision Peptide Company Inc
Canadian Securities ExchangeTotal Valuation
Precision Peptide Company Inc carries a market capitalization of 20.78M, placing it among publicly traded companies globally.
| Market Cap | 20.78M |
| Enterprise Value | N/A |
Share Statistics
Precision Peptide Company Inc currently has 28.17M shares outstanding.
| Shares Outstanding | 28.17M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3,839.69, and the price-to-book ratio stands at 3.47.
| PE Ratio | N/A |
| PS Ratio | 3,839.69 |
| PB Ratio | 3.47 |
| P/TBV Ratio | -35.92 |
| P/FCF Ratio | -4.48 |
| P/OCF Ratio | -4.48 |
Financial Position
Precision Peptide Company Inc maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.44 |
| Quick Ratio | 0.36 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -58.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Precision Peptide Company Inc's stock has gained approximately 22.22222% over the past 52 weeks. The 50-day moving average sits at 0.47, while the 200-day moving average is 0.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | 22.22222% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Precision Peptide Company Inc generated 1,080.00 in revenue and converted that into -1.07M in net income, yielding earnings per share of -0.10. EBITDA reached -966,091.00, while operating income came in at -967,643.00.
| Revenue | 1,080.00 |
| Gross Profit | 3,475.00 |
| Operating Income | -967,643.00 |
| Pretax Income | -1.07M |
| Net Income | -1.07M |
| EBITDA | -966,091.00 |
| EBIT | -967,643.00 |
| Earnings Per Share (EPS) | -0.10 |
Balance Sheet
Total book value stands at 3.04M, with working capital of -294,116.00 providing operational flexibility.
| Cash & Cash Equivalents | 144,845.00 |
| Total Debt | N/A |
| Net Debt | -143,879.00 |
| Equity (Book Value) | 3.04M |
| Book Value Per Share | 0.11 |
| Working Capital | -294,116.00 |
Cash Flow
Precision Peptide Company Inc produced -925,566.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -925,566.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -925,566.00 |
| FCF Per Share | -0.08 |
Margins
Precision Peptide Company Inc operates with a gross margin of 321.76, reflecting its pricing power and cost economics. The operating margin of -89,596.57 and net profit margin of -98,687.41 provide insight into operational efficiency.
| Gross Margin | 321.76 |
| Operating Margin | -89,596.57 |
| Pretax Margin | -98,687.41 |
| Profit Margin | -98,687.41 |
| EBITDA Margin | -89,452.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.31 |
| FCF Yield | -22.32 |
Scores
Precision Peptide Company Inc posts an Altman Z-Score of -31.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.14 |